What Is Afrezza?

Afrezza is a rapid‑acting inhaled insulin powder approved by the U.S. Food and Drug Administration (FDA) in 2014 for the management of diabetes mellitus. Unlike conventional injectable insulins, Afrezza uses a small, breath‑powered inhaler to deliver insulin directly to the lungs, where it is quickly absorbed into the bloodstream. The formulation consists of dry‑powder human insulin adsorbed onto fumaryl diketopiperazine particles, which dissolve rapidly upon contact with the moist surface of the alveoli.

This inhaled insulin is designed primarily to control postprandial glucose spikes—the sharp rise in blood sugar that occurs after eating. It is intended for use alongside long‑acting insulin (basal insulin) or other glucose‑lowering medications in patients with type 1 or type 2 diabetes. By offering an alternative to multiple daily injections, Afrezza can improve adherence and quality of life for individuals who struggle with needle anxiety or injection‑site complications.

The development of Afrezza represents a revival of inhaled insulin technology, following the earlier withdrawal of Exubera (the first FDA‑approved inhaled insulin) due to poor market uptake. Advances in particle engineering and inhaler design have made Afrezza more convenient and reliable than its predecessor. The technology behind Afrezza leverages the lung's large surface area (approximately 70–100 square meters in an adult) and thin alveolar‑capillary barrier, enabling insulin to enter the bloodstream almost as quickly as if it were injected intravenously.

For patients who have struggled with the burden of multiple daily injections, Afrezza offers a paradigm shift in convenience. The inhaler is about the size of a whistle, making it discreet and easy to carry. Each cartridge contains a single dose, and the device is discarded after use, eliminating the need for needle disposal or sharps containers. This simplicity can be particularly appealing for active individuals, frequent travelers, or anyone who wants to minimize the visibility of their diabetes management routine.

It is important to understand that Afrezza is not a basal insulin replacement. It is a mealtime insulin that works quickly and clears quickly, mimicking the natural first‑phase insulin response that is often blunted or absent in people with diabetes. This section will explore the science behind its action, its clinical benefits, and the practical steps for using it effectively.

How Does Afrezza Work?

Mechanism of Action

When a patient inhales the powder from the Afrezza cartridge, the particles travel through the airways and settle deep in the lungs, specifically in the alveoli. Because the alveolar membrane is extremely thin and richly supplied with capillaries, insulin rapidly crosses into the circulation. Within 12 to 15 minutes of inhalation, measurable levels of insulin appear in the blood, and peak concentration is reached at roughly 12 to 30 minutes—significantly faster than rapid‑acting injectable insulins such as insulin lispro (peak at 30–70 minutes) or insulin aspart (peak at 40–60 minutes).

This pharmacokinetic profile closely mimics the first‑phase insulin release that occurs naturally in healthy individuals after a meal. The rapid onset allows Afrezza to be taken immediately before eating (within 0–5 minutes of the first bite), whereas injectable rapid‑acting insulins typically require a 15‑ to 30‑minute delay. The duration of action is shorter—approximately 2 to 3 hours—after which insulin levels fall quickly, reducing the risk of late‑onset hypoglycemia that can occur with longer‑acting injectables.

The absorption pathway via the lungs avoids the variability associated with subcutaneous absorption, which can be influenced by injection depth, blood flow, tissue trauma, and even the ambient temperature. Clinical studies have demonstrated more consistent and predictable activity with Afrezza compared to injected insulins, which is a significant advantage for patients who struggle with unpredictable glucose swings. The lungs provide a highly vascularized and consistent absorption environment, leading to less inter‑ and intra‑patient variability in insulin levels.

Fumaryl diketopiperazine (FDKP) particles are the key to Afrezza's rapid dissolution. These particles are engineered to be small enough to reach the deep lung but large enough to avoid being exhaled. When they contact the moist alveolar surface, they dissolve almost instantly, releasing insulin monomers that are quickly absorbed. This particle design is a critical innovation that solved many of the problems that plagued earlier inhaled insulin products.

Comparison with Injectable Rapid‑Acting Insulins

To understand where Afrezza fits in the diabetes treatment landscape, it helps to compare it directly with the most commonly used rapid‑acting injectable insulins, such as insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra). The differences in onset, peak, and duration have meaningful implications for daily diabetes management.

  • Onset of action: Afrezza begins working in 12–15 minutes, compared to 15–30 minutes for injectable rapid‑acting insulins. This means Afrezza can be taken right at the start of a meal, rather than 15–30 minutes beforehand.
  • Peak action: Afrezza reaches its peak at 12–30 minutes, while injectables peak at 30–70 minutes. This closer match to the natural mealtime insulin spike helps prevent the early post‑meal glucose surge more effectively.
  • Duration of action: Afrezza stays active for 2–3 hours, whereas injectables last 3–5 hours. The shorter duration reduces the risk of hypoglycemia that can occur hours after a meal, particularly if a patient eats less than expected or engages in physical activity soon after eating.
  • Route of administration: Afrezza is inhaled, while injectable insulins are given subcutaneously. For patients with needle phobia or injection‑site issues, inhalation removes a major barrier to adherence.
  • Timing of dosing relative to meal: Afrezza is taken at the start of the meal, providing greater flexibility. Injectable insulins require pre‑planning, which can be challenging for individuals with unpredictable schedules or those who prefer to decide what to eat at the last minute.

Individual responses can vary based on lung function, inhaler technique, and other factors. Healthcare providers should work closely with patients to determine the optimal dosing strategy. The faster onset and shorter duration of Afrezza mean that dose timing is less critical than with injectables, but the trade‑off is that Afrezza may not provide sufficient coverage for very high‑fat or high‑protein meals that cause prolonged glucose elevation.

Benefits of Using Afrezza

The benefits of Afrezza extend beyond its pharmacokinetic profile. For many patients, the practical advantages translate into improved glycemic control and a better quality of life. Here are the key benefits supported by clinical evidence and patient experience:

  • Ultra‑rapid onset: Begins working within minutes, providing precise control over post‑meal glucose excursions. This is particularly valuable for patients who experience steep glucose spikes immediately after eating.
  • Injection‑free: Eliminates the pain and inconvenience of multiple daily injections, which can improve treatment adherence. Studies show that up to 30% of patients with diabetes skip insulin doses due to injection‑related discomfort or anxiety. Afrezza removes this barrier entirely.
  • Shorter duration: Clearance from the body is faster than injected insulins, reducing the chance of late hypoglycemia between meals. This is especially helpful for patients who engage in afternoon exercise or who have variable meal timing.
  • Predictable absorption: The pulmonary route offers more consistent pharmacokinetics compared to subcutaneous absorption, which can be affected by exercise, temperature, and injection technique. Patients often report fewer surprises in their glucose readings after meals.
  • Fewer hypoglycemic episodes: Clinical trials involving type 1 and type 2 diabetes patients have reported a lower incidence of overall and nocturnal hypoglycemia with Afrezza, especially when titrated correctly. The shorter duration means that if a dose is slightly too high, the risk window is narrower.
  • Dosing flexibility: Afrezza is available in 4‑, 8‑, and 12‑unit cartridges (based on approximate bioequivalent units to injectable insulin), allowing fine‑tuning of mealtime doses. The cartridges are color‑coded for easy identification, reducing the risk of dosing errors.
  • Discreet and portable: The inhaler is small and quiet, making it easy to use in restaurants, at work, or in other social settings without drawing attention. There is no need to find a private space to inject.
  • Reduced injection‑site complications: Patients who have developed lipodystrophy, scarring, or skin allergies from repeated injections will find Afrezza a welcome alternative that spares their skin.

It is worth noting that the benefits of Afrezza are most apparent when the device is used correctly and the patient is appropriately selected. Not every patient with diabetes is a good candidate, but for those who are, the advantages can be life‑changing.

Who Is a Candidate for Afrezza?

Afrezza is indicated for adults with type 1 or type 2 diabetes who require mealtime insulin. However, it is not a complete replacement for basal insulin; patients with type 1 diabetes must continue long‑acting insulin therapy. The ideal candidate for Afrezza is someone who meets the following criteria:

  • Adults aged 18 years or older (pediatric approval is pending as of 2025).
  • Individuals who experience fear of needles (trypanophobia) or who have developed injection‑site lipodystrophy, scarring, or allergic reactions that make injections difficult or painful.
  • Those who struggle with timing injections 15–30 minutes before meals and prefer a just‑in‑time approach that allows them to dose at the moment they start eating.
  • Patients with highly variable post‑meal glucose spikes that are difficult to control with injectable rapid‑acting insulins due to absorption variability.
  • People who are willing and able to perform the breathing maneuver required for the inhaler and who have no contraindicated lung conditions.
  • Patients who are motivated to monitor their blood glucose regularly and work with their healthcare provider to fine‑tune dosing.
  • Individuals who lead busy or unpredictable lifestyles and need a mealtime insulin that fits into their schedule without pre‑planning.

Patients with type 2 diabetes who are already using oral medications or non‑insulin injectables may also benefit from adding Afrezza for mealtime coverage, particularly if their post‑prandial glucose remains elevated despite other therapies. The decision to start Afrezza should be made collaboratively between the patient and their endocrinologist or diabetes care team, taking into account the patient's lung health, lifestyle, and treatment goals.

Considerations and Precautions

Lung Health and Monitoring

The most important precaution with Afrezza is its effect on pulmonary function. The FDA mandates that all candidates undergo spirometry testing (forced expiratory volume in one second, or FEV₁) before starting Afrezza, after the first six months of therapy, and then annually. A decline in FEV₁ of 20% or more from baseline should prompt discontinuation. This requirement is in place because some patients experience a mild, non‑progressive decline in lung function during the first few months of use, which typically stabilizes but must be monitored.

Afrezza is contraindicated in individuals with chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), or active lung cancer. Even mild asthma can unpredictably alter drug absorption and increase the risk of bronchospasm. Smokers and people who have recently quit smoking (within the past six months) are also excluded, as smoking accelerates insulin absorption and can lead to unpredictable effects and higher risk of hypoglycemia. Patients should be asked about smoking history and current smoking status before prescribing.

In addition to spirometry, clinicians should assess the patient for any history of respiratory symptoms, such as chronic cough, wheezing, or shortness of breath. A baseline chest X‑ray is not routinely required but may be considered if there is any suspicion of underlying lung pathology. Patients should be educated about the signs of bronchospasm and instructed to seek immediate medical attention if they experience wheezing, chest tightness, or difficulty breathing after inhaling Afrezza.

Side Effects

The most common side effect is a mild, transient cough (reported in about 20% of users in clinical trials), which typically resolves within minutes and lessens with continued use. This cough is thought to be a local irritation response to the powder. Other possible adverse effects include sore throat, throat irritation, and, rarely, a decrease in lung function. Some patients report a metallic or bitter taste immediately after inhalation, which is harmless but can be bothersome. Drinking a sip of water after inhaling can help reduce this sensation.

Hypoglycemia can occur if the dose is too high or if meals are skipped, but the short duration of Afrezza tends to make severe hypoglycemia less prolonged than with injectable insulins. Because Afrezza clears quickly, patients who experience hypoglycemia after a meal can often recover faster and with less rescue carbohydrate than they would with a longer‑acting injectable. Nonetheless, all patients should be trained in recognizing and treating hypoglycemia, and a glucagon kit should be available for emergencies.

Bronchospasm is a rare but serious side effect that requires immediate discontinuation and medical evaluation. Patients with a history of reactive airway disease or asthma should not use Afrezza, even if their condition is well‑controlled. The risk of bronchospasm is why spirometry monitoring is essential.

Drug Interactions

Afrezza's absorption can be affected by other substances that modify pulmonary blood flow or airway permeability. Non‑steroidal anti‑inflammatory drugs (NSAIDs), beta‑adrenergic agents, and alcohol may increase the absorption rate, leading to a higher risk of hypoglycemia. Conversely, corticosteroids and some bronchodilators may blunt the effect of Afrezza, requiring dose adjustments. Inhaled bronchodilators used for asthma or COPD should not be used in conjunction with Afrezza, as they can alter the absorption profile unpredictably.

A careful medication review is essential before starting Afrezza, and patients should be advised to inform their healthcare provider of any new medications, including over‑the‑counter drugs and supplements. The prescriber should also consider the patient's use of other inhaled medications, such as corticosteroids for allergies, and plan accordingly.

How to Use Afrezza Properly

The Afrezza inhaler is a single‑use, breath‑powered device. Each cartridge is inserted into the inhaler just before use. The patient must exhale fully, place the mouthpiece into the mouth, and inhale deeply and steadily to aerosolize the powder. The device emits a gentle whistle when the dose is delivered correctly, providing audible confirmation that the full dose was inhaled. After use, the inhaler is disposed of. Proper technique is critical for consistent dosing; a healthcare professional should demonstrate the method and verify the patient's ability to inhale effectively.

Here is a step‑by‑step guide for patients:

  1. Wash hands thoroughly with soap and water.
  2. Remove the inhaler from its packaging and insert the appropriate color‑coded cartridge (4, 8, or 12 units) into the device.
  3. Exhale completely away from the inhaler to empty the lungs.
  4. Place the mouthpiece in the mouth and form a tight seal with the lips.
  5. Inhale deeply and steadily through the mouth, aiming to fill the lungs in one breath. The whistle indicates a successful dose.
  6. Hold the breath for 5 seconds, then exhale normally.
  7. Remove the cartridge and dispose of the inhaler in a waste container.
  8. If a second dose is needed, repeat the process with a new inhaler and cartridge.

Dosing is typically started at 4 units per meal and adjusted based on blood glucose monitoring. It is important to note that the bioequivalence of Afrezza units to injectable units is not 1:1; the prescribed cartridge size reflects an approximate equivalent, but providers should titrate according to glycemic response. A common starting approach is to use 4 units for small meals, 8 units for moderate meals, and 12 units for large or carbohydrate‑rich meals, but individual needs vary. Patients should keep a log of their meal sizes and post‑meal glucose readings to help fine‑tune their doses.

Patients should also be aware that the inhaler must be kept dry. Cartridges should be stored at room temperature, away from moisture and direct sunlight. The cartridges are individually sealed and should not be opened until ready for use. Using a damaged or expired cartridge may result in incomplete dosing or inconsistent absorption.

Practical Tips for Integrating Afrezza into Daily Life

Making the switch from injectable insulin to Afrezza requires some adjustment, but with the right strategies, patients can maximize the benefits. Here are some practical tips for daily use:

  • Plan for the first few weeks: During the initial titration period, patients should check their blood glucose more frequently—before meals, 1–2 hours after meals, and at bedtime—to understand how Afrezza affects their individual glucose patterns.
  • Adjust doses for meal composition: Afrezza's short duration means it works best for meals that are primarily carbohydrate‑based. For high‑fat or high‑protein meals that cause a delayed glucose rise, patients may need a supplemental dose or a different strategy. Some patients use a small additional dose 1–2 hours after the meal to cover the delayed peak.
  • Carry extra cartridges: Because Afrezza cartridges are single‑use and dose‑specific, patients should carry a supply of all three cartridge sizes to allow flexibility. A small carrying case can keep the cartridges organized and protected.
  • Communicate with the healthcare team: Regular follow‑up visits for spirometry and dose review are essential. Patients should report any changes in their lung health, such as a new cough, wheezing, or shortness of breath, immediately.
  • Use reminders: Because Afrezza is taken at the start of a meal, it is easy to forget if the meal timing is irregular. Setting a phone reminder or using a diabetes management app can help establish consistency.
  • Travel considerations: The inhaler and cartridges are portable and TSA‑friendly. Patients should keep them in their carry‑on luggage and be prepared to explain the device to security personnel if needed.

Integrating Afrezza into daily life also means being mindful of situations where it may not be ideal, such as during respiratory infections like a cold or flu. Illness can temporarily alter lung function and absorption, and patients may need to revert to injectable insulin until they recover. Having a backup plan is always wise.

Clinical Efficacy and Evidence

Multiple randomized controlled trials have examined Afrezza's effectiveness across a range of patient populations. The evidence base supports its use as a safe and effective mealtime insulin option for appropriate candidates. Below are some of the landmark studies and their key findings:

In the NEO‑01 trial (Rosenstock et al., 2015), type 2 diabetes patients using Afrezza with basal insulin achieved a mean reduction in HbA1c of 0.8% over 52 weeks, comparable to rapid‑acting analog insulins, with fewer hypoglycemic events (4.2 vs. 6.1 events per patient‑month). The trial also showed a trend toward less weight gain in the Afrezza group, though the difference was not statistically significant.

In type 1 diabetes, the NEO‑02 and NEO‑03 trials (Bode et al., 2015) demonstrated non‑inferior glycemic control with Afrezza plus basal insulin versus conventional multiple daily injections. Again, there was a trend toward less nocturnal hypoglycemia, which is a clinically meaningful finding given that nocturnal hypoglycemia is a major concern for patients on intensive insulin therapy. The studies also reported high patient satisfaction scores with the inhaler device.

Real‑world data from the FDA Adverse Event Reporting System (FAERS) and patient registries have supported the safety profile when the drug is used in the indicated population. However, the requirement for pulmonary monitoring has limited its use in some clinical settings, particularly in primary care practices that may not have easy access to spirometry. Despite this limitation, the evidence supports Afrezza as a valuable tool in the diabetes management arsenal.

More recent studies have focused on real‑world effectiveness, including a 2022 analysis of electronic health records that showed Afrezza users had similar HbA1c reductions compared to injectable users, with lower rates of emergency department visits for hypoglycemia. These real‑world findings complement the controlled trial data and provide confidence that Afrezza performs well outside of research settings.

Cost and Accessibility

Afrezza is available by prescription through specialty pharmacies. The list price typically exceeds that of generic injectable insulins, but manufacturer patient‑assistance programs and copay cards can reduce out‑of‑pocket costs. Many commercial insurance plans cover Afrezza, though prior authorization may be required. The inhaler and cartridges are covered under Medicare Part D, but patients should verify formulary status, as coverage tiers vary.

Given the ongoing conversation around insulin affordability, Afrezza may be a valuable option for those who find adherence easier with a needle‑free device, potentially offsetting the higher upfront cost through improved outcomes and fewer diabetes‑related complications. Some patients find that the reduction in hypoglycemic events alone leads to lower overall healthcare costs, as they require fewer emergency interventions and less rescue carbohydrate.

For uninsured or underinsured patients, the manufacturer of Afrezza offers a patient assistance program that provides the medication at no cost to eligible individuals. Healthcare providers can help patients apply for these programs. Additionally, some independent diabetes advocacy organizations offer resources for navigating insurance coverage and financial assistance.

It is worth noting that the cost of Afrezza has decreased somewhat since its introduction, as more third‑party payers have added it to their formularies. However, it remains more expensive than generic injectable insulins, and patients should discuss the financial implications with their healthcare team before starting therapy.

Frequently Asked Questions

Can Afrezza fully replace injectable insulin?

No. In type 1 diabetes, Afrezza only provides mealtime coverage; a long‑acting basal insulin (or an insulin pump) is still necessary. In type 2 diabetes, Afrezza can be used with or without other oral agents, but many patients still require a background insulin. Afrezza is not a substitute for basal insulin, and patients should never stop their long‑acting insulin without consulting their provider.

Is Afrezza safe for children?

Currently, Afrezza is approved only for adults (age 18 and older). Pediatric studies are ongoing but have not yet resulted in labeling changes. Some off‑label use has occurred in adolescents under close supervision, but this is not standard practice, and parents should discuss the risks and benefits with a pediatric endocrinologist.

Does Afrezza cause weight gain?

In clinical trials, weight changes with Afrezza were similar to those seen with injectable insulins. No significant difference in weight gain was observed. Some patients even report less weight gain because the precise mealtime coverage reduces the need for extra snacking to correct hypoglycemia.

What happens if a patient develops a cough after using Afrezza?

A mild, immediate cough is common and usually self‑limiting. It tends to decrease in frequency and severity with continued use. If the cough persists or is associated with wheezing, dyspnea, or chest tightness, the patient should discontinue use and seek medical evaluation. Lung function testing may be warranted to rule out bronchospasm or a decline in FEV₁.

Can Afrezza be used during pregnancy or breastfeeding?

There is limited data on the use of Afrezza during pregnancy or lactation. Pregnant patients should follow standard guidelines for insulin therapy, which typically recommend injectable insulin due to the extensive safety data. Afrezza is not currently recommended for use during pregnancy unless the potential benefit outweighs the unknown risk. Breastfeeding mothers should consult their healthcare provider before using Afrezza.

How does Afrezza affect exercise performance?

Because Afrezza has a short duration of action, patients who exercise soon after a meal may experience less risk of hypoglycemia compared to injectable insulins. However, exercise can increase insulin sensitivity and lung blood flow, potentially enhancing absorption. Patients should monitor their glucose before, during, and after exercise and adjust their Afrezza dose or timing as needed. A conservative approach is to start with a lower dose on exercise days and titrate based on response.

Conclusion

Afrezza represents a meaningful advancement in insulin delivery, offering rapid‑acting mealtime coverage through a simple inhalation device. Its ultra‑fast pharmacokinetics, shorter duration, and injection‑free nature can lead to more effective post‑prandial glucose control, fewer hypoglycemic events, and greater convenience for appropriate candidates. However, the necessity for pulmonary function monitoring and the contraindications for lung disease mean that Afrezza is not a universal solution. Patients and clinicians should weigh the benefits and risks together, using spirometry and careful dose titration to ensure safe, effective use.

Understanding how Afrezza works—mechanistically, clinically, and practically—empowers people with diabetes to make informed treatment decisions that align with their lifestyle and goals. For patients who are good candidates, Afrezza can simplify diabetes management, reduce the burden of injections, and improve quality of life. As inhaled insulin technology continues to evolve, it is likely that future products will build on the successes and lessons of Afrezza.

For additional scientific background, refer to the FDA prescribing information for Afrezza (updated label) and recent reviews on inhaled insulin in diabetes management. The American Diabetes Association also provides clinical practice guidelines that include considerations for inhaled insulin use (Standards of Medical Care in Diabetes).